Mechanistically, TRIB3‐amplified NF‐κB signaling upregulates CXCR1/2 ligands in hepatoma cells, attracting neutrophils that enhance EMT via the OSM‐STAT3 pathway, thereby diminishing sorafenib's efficacy. Here, TRIB3 is linked to hepatocellular carcinoma.